Moreover, a novel panel integrated with serum CA125, sEV-CD5L, and sEV-APOA4 showed potential value for the differential diagnosis between ovarian cancer and ovarian cystadenoma, even at their early stages. This evidence concerns the gene MUC16 and ovarian carcinoma.